FDA to Review Moderna's mRNA Flu Vaccine After Initial Rejection

The U.S. Food and Drug Administration (FDA) has decided to review Moderna's flu vaccine developed using mRNA technology, reversing an earlier decision that surprised Wall Street. Bloomberg posted on X, highlighting the public disagreement between Moderna and the FDA following the initial rejection. The review marks a significant development in the ongoing dialogue between the pharmaceutical company and the regulatory body, as Moderna seeks approval for its innovative approach to flu vaccination. The decision to reconsider the vaccine comes amid heightened interest in mRNA technology, which gained prominence during the COVID-19 pandemic. Moderna's efforts to expand its mRNA applications beyond COVID-19 vaccines have been closely watched by investors and industry experts. The FDA's reversal is expected to impact Moderna's market position and influence future regulatory decisions regarding mRNA-based treatments.